Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 6Oropharyngeal Neoplasms 5Mouth Neoplasms 5Carcinoma 5Laryngeal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Ovarian Neoplasms 3Nasopharyngeal Carcinoma 3Lung Neoplasms 3Hypopharyngeal Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Testicular Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Seminoma 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Ganglioneuroblastoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Adenocarcinoma of Lung 2Wilms Tumor 1Vulvar Neoplasms 1Uterine Neoplasms 1Teratoma 1Stomatitis 1Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7 1

Interventions

Etoposide 3Carboplatin 3atezolizumab 2tislelizumab 1pembrolizumab 1irinotecan sucrosofate 1apatinib 1Radiotherapy 1Platinum 1NPI 2358 1Immunotherapy 1Immune Checkpoint Inhibitors 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Small Cell Lung Cancer Extensive Stage × Platinum × Clear all
NCT05745350 2025-02-11

First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Recruiting
45 enrolled
Thoracic

Small Cell Lung Cancer Extensive Stage

Data powered by HemOnc (CC BY 4.0) Colophon âš¡